SONY

Product Data Sheet

Brilliant Violet 650™ anti-human CD45RA

Catalog # / Size: 2120675 / 25 tests
2120680 / 100 tests

Clone: HI100

Isotype: Mouse IgG2b, κ

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 650™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 650™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Workshop Number: IV N906

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with CD45RO FITC and CD45RA (clone HI100) Brilliant Violet 650™.

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 650™ excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 650™ is a trademark of Sirigen Group Ltd.

Application Notes: Additional reported applications (for relevant formats of this clone) include: inhibition of CD45 functions2, immunohistochemical staining of frozen tissue sections3 and formalin-fixed paraffin-embedded tissue sections4, and immunofluorescence[15,16].

Application References:

1. Knapp W, *et al.* 1989. Leucocyte Typing IV. Oxford University Press. New York.
2. Yamada T, *et al.* 2002. *J. Biol. Chem.* 277:28830. (WB, Block)
3. Weninger W, *et al.* 2003 *J. Immunol.* 170:4638. (IHC)
4. Imanguli MM, *et al.* 2009. *Blood*. 113:3620 (IHC)
5. Roque S, *et al.* 2007*. J. Immunol.* 178:8028. (FC) PubMed

6. Smeltz RB. 2007. *J. Immunol.* 178:4786. (FC) PubMed
7. Palendira U, *et al.* 2008. *Blood* (FC) PubMed
8. Kuttruff S, *et al.* 2009. *Blood* 113:358. (FC) PubMed
10. Thakral D, *et al.* 2008. *J. Immunol.* 180:7431. (FC) PubMed
11. Alanio C, *et al.* 2010. *Blood* 115:3718. (FC) PubMed
12. Iannello A, *et al.* 2010. *J. Immunol.* 184:114. (FC) PubMed
13. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
14. Guereau-de-Arellan M, *et al.* 2011. *Brain*. 134:3578. PubMed
15. Canque B, *et al.* 2000. *Blood* 96:3748. (IF)
16. Imanguli MM, *et al.* 2009. *Blood* 13:3620. (IF)

Description: CD45RA is a 205-220 kD single chain type I glycoprotein. It is an exon 4 splice variant of the tyrosine phosphatase CD45. The CD45RA isoform is expressed on resting/naïve T cells, medullary thymocytes, B cells and monocytes. CD45RA enhances both T cell receptor and B cell receptor signaling. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4. CD45 has also been reported to bind galectin-1. CD45 isoform expression can change in response to cytokines.

Antigen References:

1. Thomas M. 1989. *Annu. Rev. Immunol.* 7:339.
2. Trowbridge I, *et al.* 1994. *Annu. Rev. Immunol.*12:85.